Research Article
Prognostic Impact of Prephase Treatment Prior to First-Line Treatment in DLBCL: A Population-Based Registry Study
Table 2
Grade III-IV toxicities after the first-line regimens of diffuse large B-cell lymphoma.
| | All patients (N = 340) | Before propensity score matching | After propensity score matching | With prephase (N = 126) | Without prephase (N = 214) | | With prephase (N = 97) | Without prephase (N = 97) | |
| All toxicities | 92 (27%) | 40 (32%) | 52 (24%) | 0.14 | 25 (26%) | 27 (28%) | 0.75 | Febrile neutropenia | 23 (7%) | 15 (12%) | 8 (4%) | 0.004 | 9 (9%) | 5 (5%) | 0.27 | Neutropenia | 74 (22%) | 34 (27%) | 40 (19%) | 0.07 | 22 (23%) | 20 (21%) | 0.73 | Anemia | 13 (4%) | 8 (6%) | 5 (2%) | 0.08 | 1 (1%) | 1 (1%) | 1.00 | Thrombocytopenia | 10 (3%) | 5 (4%) | 5 (2%) | 0.51 | 4 (4%) | 2 (2%) | 0.68 | Infection | 28 (8%) | 19 (15%) | 9 (4%) | 0.0004 | 11 (11%) | 6 (6%) | 0.20 | Cardiac toxicity | 4 (1%) | 2 (2%) | 2 (1%) | 0.63 | 2 (2%) | 2 (2%) | 1.00 | Neurologic toxicity | 2 (1%) | 1 (1%) | 1 (1%) | 1.00 | 1 (1%) | 0 | 1.00 |
|
|